Supplementary materials for the study 'COVID-19 infection associated with increased risk of new-onset vascular dementia in adults ≥50 years'

Contents

Table S1. Classification of certain diseases and their ICD-10 codes in the UK Biobank3
Table S2. The ICD-10 codes of dementia in UK Biobank
Table S3. Information on missing covariates among 54,757 UK Biobank participants5
Table S4. Baseline characteristics of the 1:1 PSM dataset 2 in the UK Biobank
Figure S1. Kaplan-Meier survival curves for dementia-free probability between participants
with COVID-19 and participants with contemporary non-COVID respiratory tract diseases,
stratified by (A) all-cause dementia, (B) AD, and (C) VaD
Table S5. Hazard ratios for the risk of new-onset all-cause dementia across all subgroups,
comparing the COVID-19 group with the matched contemporary non-COVID-19 group and
the contemporary non-COVID respiratory tract diseases group
Table S6. Hazard ratios for the risk of new-onset Alzheimer's dementia across all subgroups,
comparing the COVID-19 group with the matched contemporary non-COVID-19 group and
the contemporary non-COVID respiratory tract diseases group
Figure S2. Association between COVID-19 infection and the risk of all-cause dementia across
various subgroups, compared with the non-COVID-19 group
Figure S3. Association between COVID-19 infection and the risk of all-cause dementia across
various subgroups, compared with the non-COVID-19 respiratory tract diseases group 13

Table S7. Association between COVID-19 and dementia risk compared to matched control
groups, excluding participants with less than 3 months of follow-up
Table S8. Association between COVID-19 and dementia risk compared to matched control
groups using the Fine-Gray competing risk model
Table S9. Association between COVID-19 and dementia risk through the propensity score-
matched approach with additional covariate adjustments
Table S10. Association between COVID-19 and dementia risk compared to control groups
without propensity score matching, adjusted for covariates used in matching17
Table S11. Association between COVID-19 and dementia risk compared to control groups,
with full covariate adjustment and without propensity score matching
Table S12. Association between COVID-19 identified in inpatients and dementia risk through
the propensity score-matched approach
Table S13. Association between COVID-19 identified in inpatients and dementia risk though
the propensity score match approach with additional covariate adjustments20
Table S14. Association between COVID-19 (n=16,017) and dementia risk, compared to non-
COVID respiratory infections (n=331)
Table S15. Association between COVID-19 and dementia risk in participants without baseline
neurological or psychiatric disorders, with full covariate adjustment

Table S1. Classification of certain diseases and their ICD-10 codes in the UK Biobank

Туре	ICD-10 codes
Cardiovascular diseases	
Heart failure	150
Coronary artery disease	120-25
Cardiomyopathy	I42
Neurological diseases	
Stroke	163, 164
Parkinson's disease	G20
Huntington's disease	G10
Multiple sclerosis	G35
Sleep disorders	G47
Intracranial injury	S06
Mental illnesses	
Depressive disorder	F32, F33
Schizophrenia	F20
Bipolar disorder	F31
Cancer	C00-C97

ICD-10 diagnoses were taken from linked records with dates \leq index date; no fixed look-back limit was imposed.

Table S2. The ICD-10 codes of dementia in UK Biobank

Туре	ICD-10 codes
Alzheimer's dementia	F00. F00.0, F00.1, F00.2, F00.9, G30, G30.0, G30.1, G30.8, G30.9
Vascular dementia	F01, F01.0, F01.1, F01.2, F01.3, F01.8, F01.9, I67.3
Frontotemporal dementia	F02.0, G31.0
Od	A81.0, F02, F02.1, F02.2, F02.3, F02.4, F02.8, F03, F05.1, F10.6,
Others	G31.1, G31.8

Table S3. Information on missing covariates among 54,757 UK Biobank participants

Covariates	Number of missing	Missing rates (%)
Ethnicity	313	0.57
Body mass index	430	0.79
Townsend Deprivation Index	69	0.13
Metabolic equivalent task	13,646	24.92
Smoking status	395	0.72
Alcohol intake frequency	202	0.37
Hypertension	107	0.2
Diabetes mellitus	166	0.3

Table S4. Baseline characteristics of the 1:1 PSM dataset 2 in the UK Biobank


	Covid-19	Non-COVID respiratory	CMD
Characteristics	(n=2,150)	conditions (n=2,150)	SMD
Age	71.40 ± 7.45	71.37 ± 7.34	0.00
Male, N (%)	1,127 (52.42%)	1,115 (51.86%)	0.01
White, N (%)	2,029 (94.37%)	2,036 (94.70%)	0.01
Townsend deprivation index	-1.11 ± 3.19	-1.06 ± 3.28	0.02
BMI	28.17 ± 4.62	28.06 ± 5.03	0.02
MET	2812.12 ± 2806.70	2723.22 ± 2720.51	0.03
DM, N (%)	168 (7.81%)	185 (8.60%)	0.03
Hypertension, N (%)	1282 (59.63%)	1342 (62.42%)	0.06
CVD, N (%)	324 (15.07%)	501 (23.30%)	0.21
ND, N (%)	158 (7.35%)	250 (11.63%)	0.15
MI, N (%)	116 (5.40%)	222 (10.33%)	0.18
Cancer, N (%)	437 (20.33%)	692 (32.19%)	0.27
Vaccinations, N (%)			0.10
No	1523 (70.84%)	1581 (73.53%)	
1dose	383 (17.81%)	306 (14.23%)	
2 doses	244 (11.35%)	263 (12.23%)	
Smoking status, N (%)			0.21
Never	821 (38.19%)	717 (33.35%)	
Previous	1139 (52.98%)	1099 (51.12%)	
Current	190 (8.84%)	334 (15.53%)	
Alcohol intake frequency, N (%)			0.08
Never	203 (9.44%)	198 (9.21%)	
Special occasions only	225 (10.47%)	238 (11.07%)	
One to three times a month	218 (10.14%)	225 (10.47%)	
Once or twice a week	578 (26.88%)	529 (24.60%)	
Three or four times a week	496 (23.07%)	472 (21.95%)	
Daily or almost daily	430 (20.00%)	488 (22.70%)	

BMI, Body mass index; MET, Metabolic equivalent task; DM, Diabetes mellitus; CVD, Cardiovascular diseases; ND, Neurological diseases; MI, Mental illnesses; SMD, standardized mean difference; PSM, propensity score match.

In this study, neurological diseases are defined as including stroke, Parkinson's disease, Huntington's disease, multiple sclerosis,

sleep disorders, and intracranial injury. Mental illnesses are defined as including depression, schizophrenia, and bipolar disorder. Cardiovascular diseases encompass heart failure, coronary artery disease, and cardiomyopathy.

Figure S1. Kaplan-Meier survival curves for dementia-free probability between participants with COVID-19 and participants with contemporary non-COVID respiratory tract diseases, stratified by (A) all-cause dementia, (B) AD, and (C) VaD



AD: Alzheimer's dementia; VaD: Vascular dementia.

In this figure, "control" represents participants with matched contemporary non-COVID respiratory tract diseases.

Table S5. Hazard ratios for the risk of new-onset all-cause dementia across all subgroups, comparing the COVID-19 group with the matched contemporary non-COVID-19 group and the contemporary non-COVID respiratory tract diseases group

T	COVID-19 group (n=16,017) vs. Contemporary non-COVID-19 group (n=16,017)					COVID-19 group (n=2,150) vs. Contemporary respiratory tract diseases group (n=2,150)			
Type									
Subgroups	Cases	HR (95% CI)	р	P for interaction	Cases	HR (95% CI)	p	P for interaction	
Sex				0.028				0.79	
Women	142	1.27 (0.91-1.77)	0.155		32	0.67 (0.33-1.37)	0.269		
Men	194	1.52 (1.14-2.02)	0.004		41	1.20 (0.64-2.23)	0.566		
Age				< 0.001				0.025	
<65years	23	0.55 (0.23-1.30)	0.173		3	0.60 (0.05-6.94)	0.683		
≥65 years	313	1.59 (1.27-2.00)	< 0.001		70	0.94 (0.58-1.51)	0.792		
Ethnicity				0.03				0.916	
Non-White	19	1.99 (0.76-5.24)	0.163		3	0.43 (0.04-4.79)	0.496		
White	317	1.39 (1.11-1.74)	0.004		70	0.96 (0.60-1.54)	0.863		
BMI				0.335				0.977	
$<30 \text{ kg/m}^2$	223	1.44 (1.11-1.89)	0.007		53	0.99 (0.57-1.70)	0.968		
$\geq 30 \text{ kg/m}^2$	113	1.34 (0.92-1.94)	0.126		20	0.78 (0.32-1.91)	0.593		
Alcohol intake fro	equency			0.017				0.615	
Less than weekly	146	1.35 (0.97-1.87)	0.075		27	1.16 (0.53-2.51)	0.711		
Weekly or more	190	1.46 (1.09-1.95)	0.011		46	0.83 (0.46-1.48)	0.524		
Smoking status				0.116				0.336	
Never	124	1.54 (1.07-2.20)	0.019		27	1.45 (0.66-3.19)	0.361		
Ever	212	1.34 (1.02-1.76)	0.036		46	0.72 (0.40-1.30)	0.275		
Hypertension				< 0.001				0.067	
No	88	1.10 (0.72-1.68)	0.646		17	0.91 (0.34-2.42)	0.849		
Yes	248	1.60 (1.24-2.07)	< 0.001		56	0.95 (0.56-1.62)	0.863		
Diabetes mellitus				< 0.001				0.088	

265	1.36 (1.06-1.73)	0.014		63	0.98 (0.60-1.62)	0.952	
71	1.68 (1.04-2.71)	0.033		10	0.69 (0.19-2.44)	0.563	
r diseases			< 0.001				0.218
215	1.36 (1.03-1.78)	0.028		50	0.80 (0.46-1.41)	0.445	
121	1.79 (1.25-2.57)	0.002		23	1.59 (0.69-3.63)	0.273	
liseases			< 0.001				< 0.001
231	1.36 (1.05-1.77)	0.02		50	0.97 (0.55-1.7)	0.914	
105	1.85 (1.26-2.73)	0.002		23	1.18 (0.51-2.7)	0.703	
es			0.001				0.954
269	1.35 (1.06-1.71)	0.016		66	0.89 (0.55-1.45)	0.643	
67	2.10 (1.29-3.42)	0.003		7	1.55 (0.33-7.21)	0.574	
			0.047				0.362
254	1.38 (1.08-1.77)	0.011		56	1.55 (0.33-7.21)	0.412	
82	1.70 (1.10-2.63)	0.017		17	1.51 (0.58-3.91)	0.4	
			< 0.001				0.005
324	1.46 (1.17-1.82)	0.001		71	0.97 (0.61-1.56)	0.905	
12	1.34 (0.43-4.22)	0.617		2	0 (0-inf)	0.999	
	71 ar diseases 215 121 diseases 231 105 es 269 67 254 82	71	71	71	71	71	71

HR: Hazard Ratio; CI: Confidence Interval; BMI: body mass index.

The subgroup categorized by 'Physical activity' was not analysed due to a high value missing rate (n= 13,646, 24.92%).

^{&#}x27;Cases' refer to the total number of incident dementia events observed in both the COVID-19 group and the comparator group.

Table S6. Hazard ratios for the risk of new-onset Alzheimer's dementia across all subgroups, comparing the COVID-19 group with the matched contemporary non-COVID-19 group and the contemporary non-COVID respiratory tract diseases group


T	CC	OVID-19 group (n=1	6,017) vs.	Contemporary		COVID-19 group (n=2,150) vs. Contemporary			
Type	non-COVID-19 group (n=16,017)					respiratory tract diseases group (n=2,150)			
Subgroups	Cases	HR (95% CI)	р	P for interaction	Cases	HR (95% CI)	p	P for interaction	
Sex				0.607				0.445	
Women	49	1.01 (0.58-1.78)	0.959		5	1.95 (0.29-13.2)	0.496		
Men	53	1.17 (0.68-2.00)	0.580		11	1.97 (0.56-6.98)	0.293		
Age				< 0.001				0.996	
<65years	7	1.44 (0.32-6.51)	0.637		1	inf (0-inf)	0.999		
≥65 years	95	1.12 (0.75-1.68)	0.571		15	1.66 (0.57-4.84)	0.356		
Ethnicity				0.381				0.998	
Non-White	7	1.24 (0.28-5.52)	0.781		0	inf (0-inf)	0.781		
White	95	1.09 (0.73-1.63)	0.688		16	1.96 (0.68-5.62)	0.210		
BMI				0.385				0.838	
$<30 \text{ kg/m}^2$	66	1.13 (0.69-1.83)	0.634		13	2.52 (0.75-8.50)	0.137		
$\geq 30 \text{ kg/m}^2$	36	1.03 (0.54-1.99)	0.925		3	0.69 (0.06-8.42)	0.772		
Alcohol intake fro	equency			0.017				0.615	
Less than weekly	46	0.90 (0.50-1.62)	0.728		4	6.64 (0.6-72.86)	0.122		
Weekly or more	56	1.28 (0.75-2.16)	0.367		12	1.39 (0.43-4.51)	0.578		
Smoking status				0.116				0.336	
Never	37	0.96 (0.50-1.82)	0.892		5	1.24 (0.21-7.42)	0.815		
Ever	65	1.18 (0.72-1.92)	0.512		11	2.46 (0.68-8.99)	0.172		
Hypertension				< 0.001				0.067	
No	28	1.36 (0.64-2.89)	0.427		5	8.65 (0.9-83.59)	0.062		
Yes	74	1.05 (0.66-1.65)	0.850		11	1.12 (0.34-3.67)	0.854		
Diabetes mellitus				< 0.001				0.088	

No	82	1.27 (0.82-1.96)	0.286		15	2.41 (0.79-7.40)	0.124	
Yes	20	0.59 (0.24-1.49)	0.265		1	0 (0-inf)	0.999	
Cardiovascu	lar diseases			< 0.001				0.218
No	71	1.17 (0.73-1.87)	0.516		12	2.41 (0.68-8.51)	0.171	
Yes	31	1.10 (0.54-2.23)	0.800		4	1.34 (0.19-9.54)	0.769	
Neurological	diseases			< 0.001				< 0.001
No	81	1.10 (0.71-1.71)	0.666		12	2.16 (0.63-7.47)	0.222	
Yes	21	1.23 (0.52-2.91)	0.639		4	1.94 (0.25-14.8)	0.524	
Mental illnes	ses			0.001				0.954
No	83	1.02 (0.66-1.57)	0.933		15	1.50 (0.52-4.33)	0.450	
Yes	19	1.82 (0.73-4.55)	0.197		1	inf (0-inf)	0.999	
Cancer				0.276				0.784
No	81	1.18 (0.76-1.83)	0.460		11	2.07 (0.57-7.54)	0.272	
Yes	21	0.86 (0.36-2.09)	0.746		5	2.12 (0.35-12.7)	0.412	
Vaccination				0.002				0.002
No	98	1.09 (0.73-1.62)	0.681		16	1.93 (0.67-5.50)	0.221	
Yes	4	2.87 (0.30-27.6)	0.361		0	0 (0-inf)	0.999	
No		` /		0.002		,		0.002

HR: Hazard Ratio; CI: Confidence Interval; BMI: body mass index.


The subgroup categorized by 'Physical activity' was not analysed due to a high value missing rate (n= 13,646, 24.92%).

Figure S2. Association between COVID-19 infection and the risk of all-cause dementia across various subgroups, compared with the non-COVID-19 group



In this figure, "control" refers to the contemporary non-COVID-19 participants.

Figure S3. Association between COVID-19 infection and the risk of all-cause dementia across various subgroups, compared with the non-COVID-19 respiratory tract diseases group



In this figure, "control" refers to the contemporary non-COVID-19 respiratory tract diseases group.

Table S7. Association between COVID-19 and dementia risk compared to matched control groups, excluding participants with less than 3 months of follow-up

Types		D-19 group (n=15,90 emporary non-COV group (n=15,969)	· ·	COVID-19 group (n=2,141) vs. Contemporary respiratory tract diseases group (n=2,150)		
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p
All-cause dementia	232	1.52 (1.17-1.98)	0.002	64	1.02 (0.59-1.78)	0.933
AD	64	1.30 (0.79-2.13)	0.303	15	4.01 (1.00-15.88)	0.051
VaD	56	1.69 (1.01-2.89)	0.048	10	0.43 (0.11-1.73)	0.235

The analysis was conducted using propensity score matching, with matching performed based on age, sex, ethnicity, BMI, and vaccination status.

Table S8. Association between COVID-19 and dementia risk compared to matched control groups using the Fine-Gray competing risk model.

Types		ID-19 group (n=16,01 porary non-COVID-1	,	COVID-19 group (n=2,150) vs. Contemporary respiratory tract				
Types	(n=16,017)				diseases group (n=2,150)			
	Cases	sHR (95% CI)	p	Cases	sHR (95% CI)	p		
All-cause dementia	336	1.38 (1.11-1.71)	0.004	73	1.04 (0.65-1.66)	0.88		
AD	102	1.07 (0.72-1.59)	0.74	16	2.16 (0.71-6.63)	0.18		
VaD	77	1.73 (1.08-2.76)	0.022	14	1.00 (0.35-2.84)	0.99		

AD: Alzheimer's dementia; VaD: Vascular dementia; sHR: Subdistribution Hazard Ratio; CI: Confidence Interval The analysis was conducted using propensity score matching, with matching performed based on age, sex, ethnicity, BMI, and vaccination status.

Table S9. Association between COVID-19 and dementia risk through the propensity score-matched approach with additional covariate adjustments

Types		ID-19 group (n=16,0 porary non-COVID- (n=16,017)	*	COVID-19 group (n=2,150) vs. Contemporary respiratory tract diseases group (n=2,150)		
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p
All-cause dementia	336	1.58 (1.27-1.97)	< 0.001	73	1.08 (0.68-1.74)	0.736
AD	102	1.16 (0.79-1.72)	0.452	16	2.19 (0.75-6.38)	0.15
VaD	77	2.05 (1.29-3.27)	0.002	14	1.09 (0.37-3.24)	0.872

The analysis was conducted using propensity score matching, where matching was performed based on age, sex, ethnicity, BMI, and vaccinations. To further assess the impact of additional covariates, the models were additionally adjusted for MET, hypertension, diabetes mellitus, cardiovascular diseases, mental illnesses, neurological disorders, cancer, alcohol consumption frequency, and smoking status.

Table S10. Association between COVID-19 and dementia risk compared to control groups without propensity score matching, adjusted for covariates used in matching

Types	COVID-19 group (n=16,017) vs. Contemporary non-COVID-19 group (n=38,740)			COVID-19 group (n=16,017) vs. Contemporary respiratory tract diseases group (n=2,150)		
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p
All-cause dementia	701	1.59 (1.34-1.88)	< 0.001	229	1.34 (0.94-1.91)	0.107
AD	218	1.30 (0.94-1.78)	0.108	58	2.24 (0.95-5.26)	0.065
VaD	140	2.34 (1.64-3.33)	< 0.001	55	1.88 (0.85-4.18)	0.122

The models were adjusted for the same covariates as in propensity score matching, including age, sex, ethnicity, BMI and vaccination status.

Table S11. Association between COVID-19 and dementia risk compared to control groups, with full covariate adjustment and without propensity score matching

Types		COVID-19 group (n=16,017) vs. Contemporary non-COVID-19 group (n=38,740)			COVID-19 group (n=16,017) vs. Contemporary respiratory tract diseases group (n=2,150)		
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p	
All-cause dementia	701	1.54 (1.3-1.83)	< 0.001	229	1.29 (0.90-1.84)	0.169	
AD	218	1.27 (0.92-1.74)	0.143	58	2.15 (0.91-5.06)	0.081	
VaD	140	2.23 (1.56-3.18)	< 0.001	55	1.77 (0.8-3.92)	0.161	

The models were fully adjusted for age, sex, ethnicity, BMI, MET, hypertension, diabetes mellitus, cardiovascular diseases, mental illnesses, neurological disorders, cancer, alcohol consumption frequency, smoking status, and vaccination status.

Table S12. Association between COVID-19 identified in inpatients and dementia risk through the propensity score-matched approach

Types	COVID-19 group (n=3,442) vs.			COVID-19 group (n=2,150) vs.			
	Contemporary non-COVID-19 group			Contemporary respiratory tract			
	(n=3,442)			diseases group (n=2,150)			
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p	
All-cause dementia	133	1.89 (1.33-2.66)	< 0.001	88	1.58 (1.04-2.42)	0.033	
AD	28	0.99 (0.47-2.12)	0.988	12	1.15 (1.15-3.57)	0.809	
VaD	31	2.56 (1.23-5.36)	0.012	23	2.67 (1.10-6.50)	0.03	

The analysis was conducted using propensity score matching, where matching was performed based on age, sex, ethnicity, BMI, and vaccinations.

Table S13. Association between COVID-19 identified in inpatients and dementia risk though the propensity score match approach with additional covariate adjustments

Types	COVID-19 group (n=3,442) vs. Contemporary non-COVID-19 group (n=3,442)			COVID-19 group (n=2,150) vs. Contemporary respiratory tract diseases group (n=2,150)		
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p
All-cause dementia	133	1.79 (1.26-2.54)	0.001	88	1.30 (0.84-2.01)	0.234
AD	28	0.88 (0.41-1.89)	0.742	12	0.98 (0.31-3.11)	0.969
VaD	31	2.42 (1.15-5.10)	0.019	23	1.79 (0.72-4.48)	0.212

The analysis was conducted using propensity score matching, where matching was performed based on age, sex, ethnicity, BMI, and vaccinations. To further assess the impact of additional covariates, the models were additionally adjusted for MET, hypertension, diabetes mellitus, cardiovascular diseases, mental illnesses, neurological disorders, cancer, alcohol consumption frequency, and smoking status.

Table S14. Association between COVID-19 (n=16,017) and dementia risk, compared to non-COVID respiratory infections (n=331)

Туре	Model 1			Model 2		
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p
All-cause dementia	199	1.33 (0.62-2.83)	0.461	199	1.30 (0.61-2.78)	0.497
AD	52	N/A	N/A	52	N/A	N/A
VaD	49	2.47 (0.34-17.93)	0.373	49	2.52 (0.35-18.38)	0.362

Model 1 was adjusted for age, sex, ethnicity, BMI, and vaccination status. Model 2 was additionally adjusted for MET, hypertension, diabetes mellitus, cardiovascular diseases, mental illnesses, neurological disorders, cancer, alcohol consumption frequency, and smoking status.

Table S15. Association between COVID-19 and dementia risk in participants without baseline neurological or psychiatric disorders, with full covariate adjustment

Types		ID-19 group (n=13,66 porary non-COVID-1	1	COVID-19 group (n=13,662) vs. Contemporary respiratory tract diseases			
		(n=31,994)		(n=1,725)			
	Cases	HR (95% CI)	p	Cases	HR (95% CI)	p	
Dementia	422	1.45 (1.16-1.82)	0.001	129	1.26 (0.78-2.02)	0.346	
AD	158	1.14 (0.77-1.68)	0.512	38	1.87 (0.65-5.38)	0.081	
VaD	73	2.30 (1.40-3.77)	0.001	27	3.54 (0.83-15.15)	0.088	

The analysis excluded participants with any recorded diagnosis of major neurological or psychiatric disorders at baseline (e.g., stroke, Parkinson's disease, multiple sclerosis, depressive disorder, schizophrenia, or bipolar disorder). Models were fully adjusted for age, sex, ethnicity, BMI, MET, hypertension, diabetes mellitus, cardiovascular diseases, cancer, alcohol consumption frequency, smoking status, and COVID-19 vaccination status.